Stay updated on XZP-5955 Tablets in NTRK/ROS1+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the XZP-5955 Tablets in NTRK/ROS1+ Solid Tumors Clinical Trial page.

Latest updates to the XZP-5955 Tablets in NTRK/ROS1+ Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedA new revision entry v3.3.4 was added to the record history, and the previous revision v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page now shows a new 'Revision: v3.3.3' label and the 'HHS Vulnerability Disclosure' link has been removed (and 'Revision: v3.3.2' is no longer listed). These are minor administrative updates to the page footer and revision history.SummaryDifference0.2%

- Check52 days agoChange DetectedA new revision (v3.3.2) was added to the record history and an older revision (v3.2.0) was removed from the list; these are minor metadata updates that do not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page no longer displays the government funding lapse notice at the top; the rest of the content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check74 days agoChange DetectedVersion 2 (2022-05-17) updated Recruitment Status; Version 3 (2022-08-28) updated Study Status.SummaryDifference0.1%

- Check102 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0.SummaryDifference13%

Stay in the know with updates to XZP-5955 Tablets in NTRK/ROS1+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XZP-5955 Tablets in NTRK/ROS1+ Solid Tumors Clinical Trial page.